Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by M.D. Anderson Cancer Center
Sponsor:
Collaborator:
Incyte Corporation
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT01751425
First received: December 14, 2012
Last updated: July 18, 2014
Last verified: July 2014

December 14, 2012
July 18, 2014
July 2013
July 2019   (final data collection date for primary outcome measure)
Maximum Tolerated Dose (MTD) for Ruxolitinib and Tyrosine Kinase Inhibitors (TKIs). [ Time Frame: 12 months from start of therapy ] [ Designated as safety issue: Yes ]
MTD is highest dose level at which 6 patients were treated and at most 1 patient experienced a dose limiting toxicity (DLT). Non-hematologic DLT defined as grade 3 or 4 elevation of ALT or AST possibly related to tyrosine kinase inhibitor (TKI). Hematologic DLT defined as grade 4 neutropenia, anemia, and/or thrombocytopenia lasting for 4 weeks or more.
Maximum Tolerated Dose (MTD) for Ruxolitinib and Tyrosine Kinase Inhibitors (TKIs). [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
MTD is highest dose level at which 6 patients were treated and at most 1 patient experienced a dose limiting toxicity (DLT).
Complete list of historical versions of study NCT01751425 on ClinicalTrials.gov Archive Site
Clinical Activity of Ruxolitinib and Tyrosine Kinase Inhibitor (TKI) [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
Primary endpoint to determine if residual disease as measured by PCR can decrease by at least 1 log or become undetectable within 12 months from the start of study therapy. Progression defined as confirmed loss of complete cytogenetic response (CCyR) for patients who enter study with this response. "Confirmed" is defined here as assessed in two consecutive cytogenetic analyses separated by at least a month. Before each cycle for the first 3 cycles, then every 3-6 cycles for the first year, then every 6-12 cycles after that, blood (about 1 tablespoon) drawn for molecular testing.
Clinical Activity of Ruxolitinib and Tyrosine Kinase Inhibitor (TKI) [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
Primary endpoint is to determine if residual disease as measured by PCR can decrease by at least 1 log or become undetectable within 12 months from the start of study therapy. Progression defined as a confirmed loss of complete cytogenetic response (CCyR) (i.e., >0% Ph+ metaphases among 20 metaphases counted by karyotype, or >10% positive by FISH) for patients who enter the study with this response. "Confirmed" is defined here as assessed in two consecutive cytogenetic analyses separated by at least a month. Survival endpoints (overall, event-free and free from blastic transformation) measured from the time of start of ruxolitinib therapy.
Not Provided
Not Provided
 
Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
Phase I-II Study of Ruxolitinib (INCB18424) for Patients With Chronic Myeloid Leukemia (CML) With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

This is a 2 part study. The goal of the first part of this clinical research study is to find the highest tolerable dose of ruxolitinib that can be given with a TKI that you are already taking (such as gleevec, sprycel, or nilotinib) as part of your standard of care treatment. The goal of the second part of this study is to learn if this drug combination can help to control CML. Although you have a good response to therapy, the disease is still detectable at low levels (this is called "minimal residual disease"). Researchers believe that eliminating all detectable evidence of disease may decrease the chances that the leukemia will ever come back. The safety of the drug combination will also be studied in both parts.

Ruxolitinib is designed to block a protein called Jak2 that may help keep some leukemia cells alive even with TKI therapy. Blocking this protein may cause the cells to die.

Study Drug Administration:

If you are found to be eligible to take part in this study, you will continue receiving the same TKI at the dose you had been receiving for the last 6 months.

You will also receive ruxolitinib by mouth 1 or 2 times daily. The dose level and how often you take the drug will depend on when you enter the study. The study staff will give you more detailed instructions about how often you will take the drug and what you should do if you vomit or miss a dose of study drug.

In the first part of the study, you will be assigned to a dose level of ruxolitinib based on when you join this study. Up to 3 dose levels of ruxolitinib will be tested. At least 3 participants will be enrolled at each dose level. The first group of participants will receive the lowest dose level. Each new group will receive a higher dose than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of ruxolitinib is found. This is called the Dose Escalation Group.

After the highest tolerated dose has been found, an extra 30 participants will receive ruxolitinib at that dose level. This is called the Dose Expansion Group.

Study Visits:

At every visit, you will be asked about any side effects you may have had and to list any drugs you may be taking.

Every 1-2 weeks for 8 weeks, then at Month 3 (+/- 3 weeks) and every 3 months after that, blood (about 2 teaspoons) will be drawn for routine tests and to test your kidney and liver function.

Every month for the first 3 months, then every 3-6 months for the first year, then every 6-12 months after that, blood (about 1 tablespoon) drawn for molecular testing.

Every 3-6 months for the first year, then every 6-12 months after that you will have a bone marrow aspirate to check the status of the disease.

At Weeks 1 (+/- 3 days) and 4 (+/- 1 week), Months 3 and 6 (+/- 1 month), then every 6-12 months after that, you will have a complete physical exam.

If the study doctor decides that this is in your best interest, you may be able to stop taking the study drug and/or your TKI. If you stop the study drug and/or TKI, every 4 weeks for the first 6 months after you stop treatment, then every 3 months for the next 12 months, and then every 6 months after that , blood (about 1 tablespoon) will be drawn for molecular testing. Your doctor will discuss this with you.

Length of Study:

You may continue taking the study drug for up to 2 years as long as the doctor thinks it is in your best interest. You will no longer be able to take the study drug if the disease gets worse, if intolerable side effects occur, or if you are unable to follow study directions.

Your participation on the study will be over after you have completed both the end-of-treatment and follow-up visits.

End-of-Treatment Visits:

After your last dose of study drug, you will be called or you will come in to the clinic within 30 days and you will be asked about any side effects and/or symptoms you may be having. If you are contacted by phone, the call should last about 2-3 minutes.

This is an investigational study. TKIs are approved for the treatment of CML and are given as part of your standard of care, even if you do not participate in this study. Ruxolitinib is FDA approved and commercially available for the treatment of patients with myelofibrosis. The combination of these drugs to treat CML is investigational.

Up to 48 patients will take part in this study. All will be enrolled at MD Anderson.

Interventional
Phase 1
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Leukemia
  • Drug: Ruxolitinib

    Phase I Dose Escalation Group: Ruxolitinib starting dose level 5 mg orally, twice daily.

    Phase II Dose Expansion Group: Ruxolitinib starting dose level MTD from Phase I.

    Other Names:
    • Jakafi
    • INCB018424
    • INC424
  • Drug: TKI
    Phase I Dose Escalation Group and Phase II Dose Expansion Group: Patients continue receiving commercially available TKIs (IM, NIL or DAS) at dose they had been receiving during the last 6 months.
    Other Name: Tyrosine kinase inhibitor
Experimental: Ruxolitinib + TKI

Phase I Dose Escalation Group: Ruxolitinib starting dose level 5 mg orally, twice daily. Patients continue receiving commercially available TKIs (IM, NIL or DAS) at dose they had been receiving during the last 6 months.

Phase II Dose Expansion Group: Ruxolitinib starting dose level MTD from Phase I Dose Escalation Group. Patients continue receiving commercially available TKIs (IM, NIL or DAS) at dose they had been receiving during the last 6 months.

Once MTD is defined for imatinib in the phase I portion of the study the phase 2 portion of the study will start with imatinib only. The phase I portion of the study with dasatinib and nilotinib will open once MTD is defined for the imatinib-based combination.

Interventions:
  • Drug: Ruxolitinib
  • Drug: TKI
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
48
Not Provided
July 2019   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patients 18 years or older with Philadelphia chromosome (Ph)-positive or BCR/ABL-positive CML (as determined by cytogenetics, FISH, or PCR).
  2. Patients must be on continuous TKI therapy for management of their CML. Any commercially available and FDA- approved TKI can be used, i.e., imatinib mesylate (IM), nilotinib (NIL) or dasatinib (DAS). Patients may be receiving TKI at entry in the frontline or salvage setting, including patients currently on imatinib after alpha-interferon failure or on dasatinib or nilotinib after failure to prior therapy including imatinib.
  3. Patients must have received the current TKI for at least 18 months and not have increased their dose in the last 6 months.
  4. For the phase I portion of the study, patients may be included without a CCyR provided they remain in chronic or accelerated phase CML and have at least a CHR. For the Phase II portion of the study patients must be in complete cytogenetic remission (CCyR), regardless of the stage of disease they had at the time they started therapy with TKI.
  5. Patients must have detectable BCR-ABL transcript levels meeting at least 1 of the following criteria: Patient has never achieved a major molecular response (MMR, as defined by a BCR-ABL/ABL </=0.1% in the international scale (currently equivalent to 0.28 in the MDACC molecular diagnostic laboratory), & transcript levels have shown in at least 2 consecutive measures separated by at least 1 month to have increased by any value; or achieved a major molecular response which has been lost, with an interim increase in transcript levels by at least one-log, confirmed in two consecutive analyses separated by at least 1 month; or patient has received therapy for at least 2 years & lacks a sustained major molecular response; or patient has received therapy for at least 5 years & lacks a sustained complete molecular response (CMR, defined as transcript levels still detectable in the MDACC molecular diagnostic laboratory).
  6. Patients must not have had a known interruption of TKI therapy of greater than 21 consecutive days or for a total of 6 weeks in the 6 months prior to enrollment.
  7. Patients must be able to understand and sign an informed consent indicating that they are aware of the investigational nature of this study in keeping with the institutional policies.
  8. ECOG performance status </=2.
  9. Adequate organ function defined as: bilirubin <2x upper limit of normal (ULN) (unless associated with Gilbert's syndrome), and ALT or AST <2.5x ULN.
  10. ANC >/=1 x10(9)/L and platelets >/=100 x10(9)/L.
  11. Serum creatinine < 1.5 mg/dL or creatinine clearance greater or equal than 60 cc/min as defined by the Cockcroft-Gault Equation: Males(mL/min):(140-age)*IBW(kg) / 72*(serum creatinine (mg/dl)); Females (mL/min):0.85*(140-age)*IBW(kg) / 72*(serum creatinine (mg/dl)).
  12. Women of childbearing potential should be advised to avoid becoming pregnant while on therapy with Ruxolitinib and for 30 days after the last dose and practice effective methods of contraception. Men should be advised not to father a child while receiving treatment with Ruxolitinib and for 30 days after the last dose. Effective methods of contraception for this study include barrier methods (e.g., condoms, diaphragm); spermicidal jelly or foam; oral, depo provera, or injectable hormonal contraceptives; intrauterine devices; tubal ligation; and abstinence.

Exclusion Criteria:

  1. For the phase I portion of the study, patients in blast phase. For the phase II portion of the study, patients in accelerated or blast phase.
  2. Patients receiving any other investigational agents.
  3. Patients who are pregnant or breast-feeding.
  4. Patients with clinically significant heart disease (NYHA Class III or IV).
  5. Patients with QTc > 480 msec.
  6. Patients taking a potent CYP3A4 inhibitor that cannot be changed to an alternate drug.
  7. Known or suspected hypersensitivity to ruxolitinib.
  8. Patients with advanced malignant hepatic tumors.
  9. Patients with known active hepatitis B or C, or HIV infection.
  10. Patients with other medical conditions or concomitant medications that in the opinion of the principal investigator may interfere with the therapeutic treatment.
Both
18 Years and older
No
Contact: Jorge Cortes, MD 713-794-5783
United States
 
NCT01751425
2012-0697, NCI-2013-00551
No
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Incyte Corporation
Principal Investigator: Jorge Cortes, MD UT MD Anderson Cancer Center
M.D. Anderson Cancer Center
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP